Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 1135Session 2025

What changed between versions

18 paragraphs changed+71 words added−99 removed

Highlighted text was added in the newer version. Struck-through text was removed.

OFFERED FOR CONSIDERATION

1/30/2025

2025 SESSION

INTRODUCED

25102713D

SENATE BILL NO. 1135

AMENDMENT IN THE NATURE OF A SUBSTITUTE

Offered January 8, 2025

Prefiled January 7, 2025

A BILL to direct the Board of Pharmacy to promulgate regulations that allow for the prescribing, possessing, dispensing, and use of COMP360.

—————

Patron—Boysko

—————

(ProposedReferred by the Senateto Committee on Education and Health

on January 30, 2025)

(Patron Prior to Substitute—Senator Boysko)

A BILL to direct the Board of Pharmacy to promulgate regulations that allow for the prescribing, possessing, dispensing, and use of crystalline polymorph psilocybin.

—————

Be it enacted by the General Assembly of Virginia:

1. § 1. Upon approval by the U.S. Food and Drug Administration (FDA ) of the pharmaceutical composition of crystalline polymorph psilocybin, known as COMP360 or any such trade name approved by the FDA, the Board of Pharmacy shall promulgate regulations to make the following activities legal in the Commonwealth: (i) the clinically appropriate prescription for a patient of the FDA-approved pharmaceuticalprescription compositiondr ofug crystalline polymorph psilocybinCOMP360 by a health care provider licensed to prescribe medications in th e Commonwealth and acting within his authorized scope of practice; (ii) the dispensing, pursuant to a valid prescription, of the FDA-approved pharmaceuticalprescription compositiondrug of crystalline polymorph psilocybinCOMP360 to a patient or a patient's authorized representative by a pharmacist or by another health care provider licensed to dispense medications in th e Commonwealth and acting within his authorized scope of practice; (iii) the possession, distribution, and transport of the FDA-approved pharmaceuticalprescription compositiondrug of crystalline polymorph psilocybinCOMP360 by a patient to whom a valid prescription was issued or by the patient's authorized representative; (iv) the possession, distribution, and transport of the FDA-approved pharmaceuticalprescription compositiondrug of crystalline polymorph psilocybinCOMP360 by a licensed pharmacy or wholesaler in order to facilitate the appropriate dispensing and use of the drug; and (v) the use of the FDA-approved pharmaceuticalprescription compositiondrug of crystalline polymorph psilocybinCOMP360 by a patient to whom a valid prescription was issued, provided the patient uses the drug only for legitimate medical purposes in conformity with instructions from the prescriber and dispenser. AWithin t30 itsbusiness next quarterly meetingdays following rescheduling by the U.S. Drug Enforcement Administration of the pharmaceutical composition of crystalline polymorph psilocybinCOMP360, the Board of Pharmacy shall initiate rulemaking to amend its regulations in accordance with the requirements of Article 2 (§ 2.2-4006 et seq. of the Code of Virginia ) of the Administ rative Process Act to conform to the provisions of this act .

Back to the full text